Progenics Pharmaceuticals have announced that they have entered an agreement with Wyeth Pharmaceuticals under which they will be regaining all the worldwide rights to the Relistor franchise from Wyeth Pharmaceuticals. Progenics had originally licensed the drug to Wyeth Pharmaceuticals four years ago but now they would like to take back the charge over the development of a subcutaneous version of the drug after the one year transition period.http://www.favstocks.com/progenics-wyeth...
Apart from the ongoing development of Relistor drug, Progenics Pharmaceuticals will also look after the future development and commercialization of Relistor drug.